Cargando…

Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation

Proprotein convertase subtilisin/kexin-9 (PCSK9) enhances the degradation of hepatic low-density lipoprotein receptor (LDLR). Deletion of PCSK9, and loss-of-function mutants in humans result in lower levels of circulating LDL-cholesterol and a strong protection against coronary heart disease. Accord...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seidah, Nabil G., Poirier, Steve, Denis, Maxime, Parker, Rex, Miao, Bowman, Mapelli, Claudio, Prat, Annik, Wassef, Hanny, Davignon, Jean, Hajjar, Katherine A., Mayer, Gaétan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3407131/ https://www.ncbi.nlm.nih.gov/pubmed/22848640 http://dx.doi.org/10.1371/journal.pone.0041865

Ejemplares similares

The Multifaceted Biology of PCSK9
por: Seidah, Nabil G, et al.
Publicado: (2021)

The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol
por: Seidah, Nabil G.
Publicado: (2017)

Pcsk5 is required in the early cranio-cardiac mesoderm for heart development
por: Szumska, Dorota, et al.
Publicado: (2017)

PCSK9 Contributes to the Cholesterol, Glucose, and Insulin2 Homeostasis in Seminiferous Tubules and Maintenance of Immunotolerance in Testis
por: Pelletier, R.-Marc, et al.
Publicado: (2022)

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)
por: Canuel, Maryssa, et al.
Publicado: (2013)

Trafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal Domain
por: Poirier, Steve, et al.
Publicado: (2016)

The biology of PCSK9 from the endoplasmic reticulum to lysosomes: new and emerging therapeutics to control low-density lipoprotein cholesterol
por: Poirier, Steve, et al.
Publicado: (2013)

Low-density lipoprotein (LDL)-dependent uptake of Gram-positive lipoteichoic acid and Gram-negative lipopolysaccharide occurs through LDL receptor
por: Grin, Peter M., et al.
Publicado: (2018)

Expanding Biology of PCSK9: Roles in Atherosclerosis and Beyond
por: Seidah, Nabil G., et al.
Publicado: (2022)

The PCSK9 discovery, an inactive protease with varied functions in hypercholesterolemia, viral infections, and cancer
por: Seidah, Nabil G.
Publicado: (2021)

PCSK9 is not secreted from mature differentiated intestinal cells
por: Moreau, François, et al.
Publicado: (2021)

PCSK9 Prosegment Chimera as Novel Inhibitors of LDLR Degradation
por: Luna Saavedra, Yascara Grisel, et al.
Publicado: (2013)

PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity
por: Alannan, Malak, et al.
Publicado: (2022)

PCSK9 regulates the NODAL signaling pathway and cellular proliferation in hiPSCs
por: Roudaut, Meryl, et al.
Publicado: (2021)

The proprotein convertase PC5/6 is protective against intestinal tumorigenesis: in vivo mouse model
por: Sun, Xiaowei, et al.
Publicado: (2009)

Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice
por: Lebeau, Paul F., et al.
Publicado: (2019)

Evidence from a Randomized Trial That Simvastatin, but Not Ezetimibe, Upregulates Circulating PCSK9 Levels
por: Berthold, Heiner K., et al.
Publicado: (2013)

Molecular interactions of PCSK9 with an inhibitory nanobody, CAP1 and HLA-C: Functional regulation of LDLR levels
por: Fruchart Gaillard, Carole, et al.
Publicado: (2022)

Heparan sulfate proteoglycans present PCSK9 to the LDL receptor
por: Gustafsen, Camilla, et al.
Publicado: (2017)

LDL lowering effect of PCSK9 inhibition is reduced in women
por: Myasoedova, Veronika A, et al.
Publicado: (2023)

Degradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularly
por: Holla, Øystein L, et al.
Publicado: (2007)

Internalized PCSK9 dissociates from recycling LDL receptors in PCSK9-resistant SV-589 fibroblasts
por: Nguyen, My-Anh, et al.
Publicado: (2014)

Back to Basics: PCSK9 as a New Target for the LDL Receptor
por: Corral, Pablo
Publicado: (2014)

PCSK9 Functions in Atherosclerosis Are Not Limited to Plasmatic LDL-Cholesterol Regulation
por: Luquero, Aureli, et al.
Publicado: (2021)

γGT and PCSK9 variants in subjects with hyper-LDL-cholesterolemia
por: Hamasaki, Masato, et al.
Publicado: (2022)

Circulating levels of PCSK9, ANGPTL3 and Lp(a) in stage III breast cancers
por: Wong Chong, Emilie, et al.
Publicado: (2022)

Post-transcriptional Regulation of PCSK9 by miR-191, miR-222, and miR-224
por: Naeli, Parisa, et al.
Publicado: (2017)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

Transiently Elevated TC and sdLDL-C Levels and Falsely Low LDL-C Levels in Patients with Extrahepatic Cholangiocarcinoma
por: Guo, Yi, et al.
Publicado: (2021)

LDL, LDL receptors, and PCSK9 as modulators of the risk for type 2 diabetes: a focus on white adipose tissue
por: Faraj, May
Publicado: (2020)

CVD Risk Stratification in the PCSK9 Era: Is There a Role for LDL Subfractions?
por: Kjellmo, Christian Abendstein, et al.
Publicado: (2018)

PCSK9 facilitates melanoma pathogenesis via a network regulating tumor immunity
por: Gu, Yan, et al.
Publicado: (2023)

A Novel Mouse Model of Alzheimer's Disease with Chronic Estrogen Deficiency Leads to Glial Cell Activation and Hypertrophy
por: Prat, Annik, et al.
Publicado: (2011)

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents
por: Konrad, Robert J, et al.
Publicado: (2011)

Effects of LDL Receptor Modulation on Lymphatic Function
por: Milasan, Andreea, et al.
Publicado: (2016)

Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9
por: Schmidt, Amand F., et al.
Publicado: (2019)

Dengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes
por: Gan, Esther Shuyi, et al.
Publicado: (2020)

Decreased PCSK9 expression in human hepatocellular carcinoma
por: Bhat, Mamatha, et al.
Publicado: (2015)

Cell-based, bioluminescent assay for monitoring the interaction between PCSK9 and the LDL receptor
por: Duellman, Sarah J., et al.
Publicado: (2017)

In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
por: Rothgangl, Tanja, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_c56qhdm5b2tb1mv8volmevdt1g